Lam, B. Y. H. https://orcid.org/0000-0002-3638-9025
Williamson, A. https://orcid.org/0000-0002-7599-9301
Finer, S. https://orcid.org/0000-0002-2684-4653
Day, F. R. https://orcid.org/0000-0003-3789-7651
Tadross, J. A. https://orcid.org/0000-0002-8424-1252
Gonçalves Soares, A.
Wade, K. https://orcid.org/0000-0003-3362-6280
Sweeney, P.
Bedenbaugh, M. N.
Porter, D. T. https://orcid.org/0000-0002-8042-3251
Melvin, A.
Ellacott, K. L. J.
Lippert, R. N.
Buller, S.
Rosmaninho-Salgado, J.
Dowsett, G. K. C.
Ridley, K. E.
Xu, Z.
Cimino, I. https://orcid.org/0000-0003-1397-5408
Rimmington, D.
Rainbow, K.
Duckett, K.
Holmqvist, S. https://orcid.org/0000-0001-6709-6666
Khan, A. https://orcid.org/0000-0002-5189-6906
Dai, X.
Bochukova, E. G.
,
Trembath, R. C.
Martin, H. C. https://orcid.org/0000-0002-4454-9084
Coll, A. P.
Rowitch, D. H. https://orcid.org/0000-0002-0079-0060
Wareham, N. J. https://orcid.org/0000-0003-1422-2993
van Heel, D. A. https://orcid.org/0000-0002-0637-2265
Timpson, N. https://orcid.org/0000-0002-7141-9189
Simerly, R. B. https://orcid.org/0000-0001-5840-0152
Ong, K. K. https://orcid.org/0000-0003-4689-7530
Cone, R. D. https://orcid.org/0000-0003-3333-5651
Langenberg, C. https://orcid.org/0000-0002-5017-7344
Perry, J. R. B. https://orcid.org/0000-0001-6483-3771
Yeo, G. S. https://orcid.org/0000-0001-8823-3615
O’Rahilly, S. https://orcid.org/0000-0003-2199-4449
Article History
Received: 17 December 2020
Accepted: 1 October 2021
First Online: 3 November 2021
Competing interests
: S.O. has undertaken remunerated consultancy work for Pfizer, AstraZeneca, GSK and ERX Pharmaceuticals. D.A.v.H. has an unrestricted research grant from Alnylam Pharmaceuticals. P.S. and R.D.C. hold equity in Courage Therapeutics Inc. and are inventors of intellectual property optioned to Courage Therapeutics Inc. R.D.C. chairs the Scientific Advisory Board at Courage Therapeutics Inc. All remaining authors declare no competing interests.